Document:

Exhibit 10.34

 

REDACTED

Certain
identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material
and (ii) would likely cause competitive harm if publicly disclosed.

 

Amendment
Two to Development and Option Agreement

 

This
Amendment Two to the Development and Option Agreement (this "Amendment"), dated as of July 10, 2020 (the
 "Amendment Two Effective Date"), is made by and between CureVac AG, a German stock corporation with offices at
Friedrich-Miescher-Strasse 15, 72076 Tubingen, Germany ("CureVac"), and Acuitas Therapeutics Inc., a British
Columbia corporation ("Acuitas") and amends and restates the Development and Option Agreement dated April 29, 2016
(as amended by the Side Agreement and Amendment Number One dated December 1,2016) between CureVac and Acuitas (the "Development
and Option Agreement"). Each of CureVac and Acuitas may be referred to herein as a "Party" or together as
the "Parties."

 

WHEREAS,
Acuitas and CureVac entered into that certain Development and Option Agreement effective April 29"', 2016
relating to the evaluation of and options to licence Acuitas LNP Technology for the research, development, manufacture and/or
commercialisation of products incorporating Acuitas LNP Technology and CureVac Technology;

 

WHEREAS,
pursuant to the Side Agreement and Amendment Number One dated December 1, 2016 to the Development and Option Agreement,
Acuitas and CureVac agreed to include in the Work Plan the evaluation of Acuitas LNP Technology together with CureVac Technology
relating to Gene Editing and to discuss and negotiate in good faith the terms and conditions under which the Development and Option
Agreement will be amended to encompass Licensed Products useful for Gene Editing purposes;

 

WHEREAS,
CureVac and Acuitas now wish to amend the Development and Option Agreement to include therein the terms and conditions
for Exchange Licenses (as defined below);

 

NOW,
THEREFORE, in consideration of the mutual covenants and representations contained herein, and for other good and valuable
consideration, the amount and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

 

Section One.
Defined Terms. Capitalized terms not defined herein have the definitions set forth in the Development and Option Agreement.

 

Section Two.
Amendments. Article 5 of the Development and Option Agreement is hereby amended to add the following Section 5.4.

 

5.4
Exchange Licenses. CureVac may elect to designate up to [*****] of the Non-exclusive Licenses granted pursuant to this
Agreement to be Exchange Licenses. For each Non-exclusive License designated an Exchange License, CureVac will have the
option for a period of [*****] from the Amendment Two Effective Date (the "Exchange Period") to exchange the
Primary Vaccine Target and any Additional Vaccine Targets in that license for an alternate Primary Vaccine Target and any
Additional Vaccine Targets by submitting a written notice to Acuitas and following the escrow procedures set forth in
Article 4 and the Option exercise procedures in this Article 5. If the proposed new Vaccine Target(s) are not
subject to Pre-existing Restrictions, the original Vaccine Target(s) will be released by the Escrow Agent and the
designated Exchange License will convert to a license to the new Vaccine Target(s) upon payment to Acuitas of an
exchange fee of Three Million Dollars (US$3,000,000). Milestones and fees paid with respect to the Licensed Products to the
original Vaccine Targets will not be creditable against Milestones and fees earned for the Licensed Products to the new
Vaccine Targets. For clarity, CureVac will have the right to exchange [*****] Primary Vaccine Targets, and any associated
Additional Vaccine Targets, with [*****] alternate Primary Vaccine Targets, and any associated Additional Vaccine Targets and
can exercise this right either for different original Exchange Licenses or multiple times for the same original Exchange
License, or a combination of both, up to a maximum of [*****] total alternate Primary Vaccine Targets. With respect to such
Exchange Licenses, the clearance through the Escrow Agent and the Target Reservation mechanism under this Agreement, as well
as all other provisions under this Agreement addressing the Target Reservation and Option exercise with respect to the
Exchange Licenses and the Primary Vaccine Target and Additional Vaccine Targets under such Exchange Licenses will continue to
apply for the Exchange Period. This Section 5.4 shall apply accordingly to Antibodies binding to a non-human protein or
non-human antigen. Furthermore, this Section 5.4 is without prejudice to CureVac's right to change the Additional
Vaccine Targets or Antibodies (as stipulated in Section 4.2(b) of a Non-exclusive License Agreement). For further
clarity, no additional option exercise fee with respect to such new licenses for the Licensed Products to the new Vaccine
Targets is payable under the Agreement.

 

     

     

    

 

The first sentence of Section 9.6
of the Development and Option Agreement is hereby amended as follows:

 

9.6.
Survival. In addition to the termination consequences set forth in Section 9.5, the following provisions will survive termination
or expiration of this Agreement, as well as any other provision which by its terms or by the context thereof, is intended to survive
such termination: Sections 3.1 (f),3.3,5.4, 8.4,8.5, 8.7,8.8,9.4,9.5.9.6, 10.1, 10.4, 10.6,10.7, 10.9, lO.lOand 10.11 and Articles
1,6 and 7.

 

Section Three.
Amendment Execution Fee. Within  [*****] after the Amendment Two Effective Date, Cure Vac will pay to Acuitas
an amendment execution fee of Five Million Dollars (US$5,000,000).

 

Section Four.
Miscellaneous. Except as amended hereby, all other provisions of the Development and Option Agreement shall remain
unchanged and in full force and effect in accordance with their terms. In the event of a conflict between the terms and conditions
of this Amendment and the terms and conditions of the Development and Option Agreement, the terms and conditions of this Amendment
shall control.

 

This Amendment
may be executed simultaneously in two or more counterparts, and by PDF or other electronic transmission, each of which counterparts
shall be deemed an original, but all of which together shall constitute one and the same instrument, provided that all such counterparts,
in the aggregate, shall contain the signatures of all parties hereto.

 

[Signature page to
follow]

 

     

     

    

 

IN
WITNESS WHEREOF, the parties have duly executed this Amendment as of the date first written above.

 

 

	CureVac
AG	
	 	 
	 	 
	By:	/s/ Franz-Werner Haas	 
	 	(Signature)	 
	 	 	 
	Name:	Franz-Werner Haas	 
	 	 	 
	Title:	Acting CEO	 
	 	 	 
	 	 	 
	By:	/s/ Pierre Kemula	 
	 	(Signature)	 
	 	 	 
	Name:	Pierre Kemula	 
	 	 	 
	Title:	CFO	 
	 	 	 
	 	 	 
	Acuitas Therapeutics Inc.	 
	 	 
	 	 	 
	By:	/s/ T. D. Madden	 
	 	(Signature)	 
	 	 	 
	Name	Thomas Madden	 
	 	 	 
	Title:	President & CEOExhibit 4.1

 

	
        NUMBER

        HSAQ
	SHARES

 

HEALTH SCIENCES ACQUISITIONS CORPORATION
2

INCORPORATED UNDER THE LAWS OF THE CAYMAN ISLANDS

ORDINARY SHARE

 

	 	 	SEE REVERSE FOR

CERTAIN DEFINITIONS
	 	 	 
	This Certifies that	 	CUSIP G4411D 109
	is the owner of	 	 

 

FULLY PAID AND NON-ASSESSABLE ORDINARY SHARES
OF $0.0001 PAR VALUE

 

HEALTH SCIENCES ACQUISITIONS CORPORATION
2

 

transferable on the books of Health
Sciences Acquisitions Corporation 2, a Cayman Islands exempted company (the “Company”), in person or by duly
authorized attorney upon surrender of this certificate properly endorsed. This certificate is not valid unless
countersigned by the Transfer Agent and registered by the Registrar. Witness the seal of the Company and the facsimile
signatures of its duly authorized officers.

 

Dated:

 

	 	 	 
	Chairman	 	Chief Financial Officer

 

HEALTH SCIENCES ACQUISITIONS CORPORATION
2

CORPORATE

SEAL 2020

CAYMAN ISLANDS

 

     

     

    

 

HEALTH SCIENCES ACQUISITIONS CORPORATION
2

 

The Company will furnish
without charge to each shareholder who so requests the powers, designations, preferences and relative, participating, optional
or other special rights of each class of share or series thereof of the Company and the qualifications, limitations, or restrictions
of such preferences and/or rights. This certificate and the Ordinary Shares represented thereby are issued and shall be held subject
to all the provisions of the Company’s Amended and Restated Memorandum and Articles of Association and all amendments thereto
and resolutions of the Board of Directors providing for the issuance of Ordinary Shares (copies of which may be obtained from the
secretary of the Company), to all of which the holder of this certificate by acceptance hereof assents.

 

The following abbreviations,
when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according
to applicable laws or regulations:

 

TEN COM - as tenants in common

 

TEN ENT - as tenants by the entireties

 

JT TEN - as joint tenants with right of survivorship

and not as tenants in common

 	UNIF GIFT MIN ACT -	 	Custodian	 	 
	 	(Cust)	 	(Minor)	 
	 	under Uniform Gifts to Minors

	 	Act	 	 
	 	 	(State)	 

 

Additional Abbreviations may also be used
though not in the above list.

 

For value received,
___________________________ hereby sell, assign and transfer unto

 

	PLEASE INSERT SOCIAL SECURITY OR OTHER
 IDENTIFYING NUMBER OF ASSIGNEE	 
	 	 
	 	 
	 
	 
	(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE)
	 
	 
	 	shares
	of the capital stock represented by the within Certificate, and do hereby irrevocably constitute and appoint
	 	Attorney
	to transfer the said share on the books of the within named Corporation will full power of substitution in the premises.
	 	 	 	 	 	 

	Dated	 	 	 	 
	 	 	 	 	 
	 	 	 	NOTICE:	The signature to this assignment must correspond with the name as written upon the face of the certificate in every particular, without alteration or enlargement or any change whatever.

 

    2

     

    

 

	Signature(s) Guaranteed:	 
	 	 
	 	 

 

THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR
INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE
MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15).

 

The holder of this certificate shall be entitled to receive
a pro rata portion of the funds from the trust account only in the event of (i) the liquidation of the trust account upon a failure
to consummate a business combination, as described in the prospectus covering the securities, or (ii) if the holder seeks to convert
his respective shares or sells them to the Company in a tender offer, in each case in connection with (1) the consummation of a
business combination or (2) in connection with an amendment to the Company’s Amended and Restated Memorandum and Articles
of Association prior to the consummation of a business combination. In no other circumstances shall the holder have any right or
interest of any kind in or to the trust account.

 

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]